trending Market Intelligence /marketintelligence/en/news-insights/trending/tl9XGCrCtlRUxHf3kjDCbA2 content esgSubNav
In This List

JobLocationMap Q1 loss narrows YOY

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

S&P 500 Q2 2022 Sector Earnings & Revenue Data

Blog

Worldwide smartphone shipment forecast through 2026: from small drop to mild recovery

Podcast

Next in Tech | Episode 84: The bear bites M&A


JobLocationMap Q1 loss narrows YOY

Bioscience Neutraceuticals Inc. said its first-quarter normalized net income was a loss of $2,180, compared with a loss of $2,320 in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

Reported net income totaled a loss of $3,500, or a loss of 0 cents per share, compared to a loss of $3,710, or a loss of 0 cents per share, in the year-earlier period.